Menu
FDA DECISION ·
Tregzi
allogeneic regulatory T-cell immunotherapy with HSPC and T cells-vldq · Orca Bio
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with hematologic malignancies undergoing matched-donor hematopoietic stem-cell transplantation with myeloablative conditioning. The use supports blood and immune-cell reconstitution and improves chronic graft-versus-host disease-free survival.
LAMPGEN ANALYSIS
Why it matters
This adds a donor-derived graft strategy for adults undergoing transplant. Precision-T assessed chronic graft-versus-host disease-free survival against an unmanipulated allograft.
What research teams should watch
Coordinate donor matching, chain of identity, manufacturing and transplant timing. Follow graft-versus-host disease assessments and prolonged post-transplant monitoring across the care team.
PRIMARY RECORDS